Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care

Kamila Tuzim, Tomasz Tuzim, Magdalena Urbańczuk, Marcin Urbańczuk, Katarzyna Schab


Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease of brain motoneurons and spinal cord. The incidence rate of this completely incurable condition amounts to 3 to 5 patients per 100,000 inhabitants and its characteristic feature is progressing muscle weakening that leads to respiratory muscle paralysis and death within 3-4 years. Up to now, etiopathogenesis of ALS is unknown, however, more and more often the role of genotype interaction with environmental factors is suggested. Diagnosing ALS is still based on a correlation of interview and clinical picture with the results of diagnostic imaging, electrophysiological examinations and some serological tests. Despite an enormous progress that occurred in neurobiology and molecular genetics, an effective pharmacotherapy inhibiting the development of the disease has not been developed yet, and the treatment is exclusively based on a systematic symptomatic management. Due to the above, ALS treatment is still a great challenge both for the scientists and clinicians.


amyotrophic lateral sclerosis, ALS, electrophysiological examination, riluzole, edaravone, replacement ventilation.

Full Text:




Haverkamp LJ, Appel V, Appel SH Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118: 707-19.

Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC wt al Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41(2):118-30.

Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH et al A Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 2006;253(12):1642-3.

Armon C An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 2003;22:217-28.

Mulder DW, Kurland LT, Offord KP, Beard CM Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 1986;36(4):511-7.

Renton AE, Chiò A, Traynor BJ State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17(1):17-23.

Brown RH, Al-Chalabi A Amyotrophic Lateral Sclerosis. N Engl J Med 2017;377(2):162-72.

van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ et al Amyotrophic lateral sclerosis. Lancet 2017;390(10107):2084-98.

Ben Hamida M, Hentati F, Ben Hamida C Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis). Conditions combining a bilateral pyramidal syndrome with limb and bulbar amyotrophy. Brain 1990;11: 47-6.

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G et al Amyotrophic lateral sclerosis. Nat Rev Dis Primers 2017;3:17071.

Kubiszewska J., Kwieciński H Sclerosis lateralis amyotrophica. Post Nauk Med 2010;6:440-48.

Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V et al J Neurol Neurosurg Psychiatry 2008; 79:7.

Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A et al Amyotrophic lateral sclerosis. Lancet 2011;377(9769):942-55.

Ince PG, Lowe J, Shaw PJ Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24: 104-17.

Phukan J, Elamin M, Bede P, Jordan N, Gallagher L et al The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012;83(1):102-8.

Elamin M, Bede P, Byrne S, Jordan N, Gallagher L et alCognitive changes predictfunctional decline in ALS: a population-based longitudinal study. Neurology 2013;80(17):1590-7.

Swinnen B, Robberecht W The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 2014;10(11):661-70.

Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A et al Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12(3):310-22.

Abrahams S, Newton J, Niven E, Foley J, Bak TH Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15(1-2):9-14.

Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA et al The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry 2016;87(6):611-9.

Hu WT, Shelnutt M, Wilson A, Yarab N, Kelly C et al Behavior matters--cognitive predictors of survival in amyotrophic lateral sclerosis. PLoS One 2013;8(2):e57584.

Woolley SC, York MK, Moore DH, Strutt AM, Murphy J et al Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler 2010;11(3):303-11.

Brooks BR, Miller RG, Swash M, Munsat TL World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(5):293-9.

Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G et al Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993;189(3):843-6.

Miller RG, Mitchell JD, Lyon M, Moore DH Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2002;(2):CD001447. Review. Update in: Cochrane Database Syst Rev 2007;

Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347(9013):1425-31.

Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16(7):505-12.

Hardiman O, van den Berg LH Edaravone: a new treatment for ALS on the horizon? Lancet Neurol 2017;16(7):490-91.

Fujimura-Kiyono C, Kimura F, Ishida S, Nakajima H, Hosokawa T et alOnset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82(11):1244-9.

Czernuszenko A Diagnosis and treatment of neurogenic dysphagia. Otorynolaryngologia 2016;15(2): 68-74.

Radunović A, Mitsumoto H, Leigh PN Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007;6(10):913-25.

Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ et al Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5(2):140-7.

Rafiq MK, Bradburn M, Proctor AR, Billings CG, Bianchi S et al A preliminary randomized trial of the mechanical insufflator-exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2015;16(7-8):448-55.

Bucchia M, Ramirez A, Parente V, Simone C, Nizzardo M et al Therapeutic development in amyotrophic lateral sclerosis. Clin Ther 2015;37(3):668-80.



  • There are currently no refbacks.

Copyright (c) 2018 © The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski